Compare MIRM & FORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | FORM |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.4B |
| IPO Year | 2019 | 2002 |
| Metric | MIRM | FORM |
|---|---|---|
| Price | $92.00 | $83.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $157.71 | $144.70 |
| AVG Volume (30 Days) | 548.2K | ★ 1.6M |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 1.89 |
| Revenue | ★ $19,138,000.00 | N/A |
| Revenue This Year | $37.65 | $33.84 |
| Revenue Next Year | $21.04 | $24.66 |
| P/E Ratio | ★ N/A | $42.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.23 | $47.33 |
| 52 Week High | $130.00 | $160.27 |
| Indicator | MIRM | FORM |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 40.00 |
| Support Level | $87.38 | $69.88 |
| Resistance Level | $98.34 | $105.71 |
| Average True Range (ATR) | 4.20 | 6.80 |
| MACD | 0.35 | 0.26 |
| Stochastic Oscillator | 48.74 | 35.26 |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.